Literature DB >> 30566242

LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β-catenin-dependent CTNNB1-mutated HCC.

Sara Charawi1,2,3,4, Pierre-Alexandre Just1,2,3,4,5, Mathilde Savall1,2,3,4, Shirley Abitbol1,2,3,4, Massiré Traore1,2,3,4, Nolwenn Metzger1,2,3,4, Roland Ravinger1,2,3,4, Catherine Cavard1,2,3,4, Benoit Terris1,2,3,4,5, Christine Perret1,2,3,4,5.   

Abstract

Hepatocellular carcinomas (HCCs) are known to be highly heterogenous. Within the extensive histopathological and molecular heterogeneity of HCC, tumors with mutations in CTNNB1, encoding β-catenin (CTNNB1-mutated HCC), constitute a very homogeneous group. We previously characterized a distinctive metabolic and histological phenotype for CTNNB1-mutated HCC. They were found to be well-differentiated, almost never steatotic, and often cholestatic, with a microtrabecular or acinar growth pattern. Here, we investigated whether LKB1, which controls energy metabolism, cell polarity, and cell growth, mediates the specific phenotype of CTNNB1-mutated HCC. The LKB1 protein was overexpressed in CTNNB1-mutated HCC and oncogenic activation of β-catenin in human HCC cells induced the post-transcriptional accumulation of the LKB1 protein encoded by the LKB1 (STK11) gene. Hierarchical clustering, based on the expression of a murine hepatic liver Lkb1 (Stk11) signature in a human public dataset, identified a HCC cluster, composed of almost all the CTNNB1-mutated HCC, that expresses a hepatic liver LKB1 program. This was confirmed by RT-qPCR of an independent cohort of CTNNB1-mutated HCC and the suppression of the LKB1-related profile upon β-catenin silencing of CTNNB1-mutated human hepatoma cell lines. Previous studies described an epistatic relationship between LKB1 and CTNNB1 in which LKB1 acts upstream of CTNNB1. Thus, we also analyzed the consequences of Lkb1 deletion on the zonation of hepatic metabolism, known to be the hallmark of β-catenin signaling in the liver. Lkb1 was required for the establishment of metabolic zonation in the mouse liver by positively modulating β-catenin signaling. We identified positive reciprocal cross talk between the canonical Wnt pathway and LKB1, both in normal liver physiology and during tumorigenesis that likely participates in the amplification of the β-catenin signaling by LKB1 and the distinctive phenotype of the CTNNB1-mutated HCC.
Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  CTNNB1; LKB1; hepatocellular carcinoma; liver

Year:  2018        PMID: 30566242     DOI: 10.1002/path.5202

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  6 in total

Review 1.  β-Catenin signaling in hepatocellular carcinoma.

Authors:  Chuanrui Xu; Zhong Xu; Yi Zhang; Matthias Evert; Diego F Calvisi; Xin Chen
Journal:  J Clin Invest       Date:  2022-02-15       Impact factor: 14.808

2.  Loss of LKB1-NUAK1 signalling enhances NF-κB activity in a spheroid model of high-grade serous ovarian cancer.

Authors:  Adrian Buensuceso; Jamie Lee Fritz; Olga Collins; Yudith Ramos Valdés; Matthew J Borrelli; Gabriel E DiMattia; Trevor G Shepherd
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

3.  Clotrimazole Inhibits HCC Migration and Invasion by Modulating the ERK-p65 Signaling Pathway.

Authors:  Xudong Liu; Jie Gao; Yaohui Sun; Feng Zhang; Wenzhi Guo; Shuijun Zhang
Journal:  Drug Des Devel Ther       Date:  2022-03-29       Impact factor: 4.162

4.  LKB1 acts as a critical brake for the glucagon-mediated fasting response.

Authors:  Suehelay Acevedo-Acevedo; Megan L Stefkovich; Sun Woo Sophie Kang; Rory P Cunningham; Constance M Cultraro; Natalie Porat-Shliom
Journal:  Hepatol Commun       Date:  2022-03-31

5.  Wnt/β-catenin signaling regulates adipose tissue lipogenesis and adipocyte-specific loss is rigorously defended by neighboring stromal-vascular cells.

Authors:  Devika P Bagchi; Akira Nishii; Ziru Li; Jennifer B DelProposto; Callie A Corsa; Hiroyuki Mori; Julie Hardij; Brian S Learman; Carey N Lumeng; Ormond A MacDougald
Journal:  Mol Metab       Date:  2020-09-09       Impact factor: 7.422

6.  Well-differentiated liver cancers reveal the potential link between ACE2 dysfunction and metabolic breakdown.

Authors:  Lise Desquilles; Luis Cano; Gevorg Ghukasyan; Nicolas Mouchet; Clémence Landreau; Anne Corlu; Bruno Clément; Bruno Turlin; Romain Désert; Orlando Musso
Journal:  Sci Rep       Date:  2022-02-03       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.